W. Kinney

发表

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer

M. Schiffman, P. Castle, T. Lorey, 2018, Annals of Internal Medicine.

A matched study of surgically treated stage IB adenosquamous carcinoma and adenocarcinoma of the uterine cervix

S. Soong, T. Frank, R. Reynolds, 1992, International Journal of Gynecologic Cancer.

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

S. Wacholder, N. Wentzensen, P. Castle, 2012, Journal of the National Cancer Institute.

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

M. Schiffman, N. Wentzensen, P. Castle, 2019, JAMA internal medicine.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

M. Schiffman, P. Castle, T. Raine-Bennett, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variable Risk of Cervical Precancer and Cancer After a Human Papillomavirus–Positive Test

M. Schiffman, P. Castle, T. Lorey, 2011, Obstetrics and gynecology.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2017, Journal of lower genital tract disease.

The Integration of Computed Tomography and Magnetic Resonance Imaging in Treatment Planning for Gynecologic Cancer

L. Smith, M. Anderson, A. Russell, 1992, Clinical obstetrics and gynecology.

Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC).

R. Hiatt, H. Sung, G. Sawaya, 1998, Gynecologic oncology.

Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study.

S. Soong, R. Alvarez, K. Podratz, 1989, Gynecologic oncology.

Erratum: Cervical cancer control, priorities and new directions (International Journal of Cancer (2003) 108 (329-333))

J. T. Cox, P. Coursaget, F. X. Bosch, 2004 .

Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50.

W. Kinney, Y. Hung, E. Suh-Burgmann, 2014, American journal of obstetrics and gynecology.

A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting.

M. Schiffman, P. Castle, T. Lorey, 2013, Journal of virological methods.

Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry

J. Cuzick, C. Wheeler, P. Castle, 2021, Journal of the National Cancer Institute.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

M. Schiffman, P. Castle, T. Lorey, 2017, Preventive medicine.

Adherence Patterns to Extended Cervical Screening Intervals in Women Undergoing HPV and Cytology Cotesting

M. Schiffman, P. Castle, T. Lorey, 2017 .

Introduction of human papillomavirus DNA screening in the world: 15 years of experience.

Y. Qiao, S. de Sanjosé, P. Castle, 2012, Vaccine.

Why does cervical cancer occur in a state-of-the-art screening program?

M. Schiffman, P. Castle, T. Lorey, 2017, Gynecologic oncology.

Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2020, Journal of lower genital tract disease.

Increased cervical cancer risk associated with screening at longer intervals.

Mark S. DeFrancesco, T. Wright, W. Huh, 2015, Obstetrics and gynecology.

American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors

J. T. Cox, C. Wheeler, D. Harper, 2007, CA: a cancer journal for clinicians.

Safety against cervical precancer and cancer following negative human papillomavirus and Papanicolaou test results in human immunodeficiency virus-infected women.

P. Castle, T. Lorey, W. Kinney, 2012, Archives of internal medicine.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Mark Schiffman, Sholom Wacholder, Hormuzd A Katki, 2011, The Lancet. Oncology.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years

M. Schiffman, P. Castle, T. Lorey, 2018, Cancer Prevention Research.

Premature conclusions on HPV-only testing – Authors' reply

S. Wacholder, M. Schiffman, P. Castle, 2011 .

Comparison of the cobas Human Papillomavirus (HPV) Test with the Hybrid Capture 2 and Linear Array HPV DNA Tests

M. Schiffman, P. Castle, T. Lorey, 2011, Journal of Clinical Microbiology.

Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan.

R. Hiatt, H. Sung, G. Sawaya, 2001, Cancer.

Lessons From Practice: Risk of CIN 3 or Cancer Associated With an LSIL or HPV-Positive ASC-US Screening Result in Women Aged 21 to 24

J. T. Cox, P. Castle, T. Lorey, 2010, Journal of lower genital tract disease.

Where's the High‐Grade Cervical Neoplasia? The Importance of Minimally Abnormal Papanicolaou Diagnoses

L. Hurley, W. Kinney, M. Manos, 1998, Obstetrics and gynecology.

A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs

M. Schiffman, P. Castle, T. Raine-Bennett, 2020, EClinicalMedicine.

On Maintaining the Balance

W. Kinney, Betty Suh-Burgmann, 2006, Journal of lower genital tract disease.

Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva.

J. Gonzalez Bosquet, K. Podratz, J. Magrina, 2003, International journal of radiation oncology, biology, physics.

Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer.

L. Smith, L. Smith, G. Leiserowitz, 1997, Gynecologic oncology.

Second-look operation in ovarian cancer.

K. Podratz, W. Kinney, 1993, Cancer.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy

M. Schiffman, N. Wentzensen, P. Castle, 2018, Journal of lower genital tract disease.

Wertheim hysterectomy in the geriatric population.

K. Podratz, W. Kinney, E. V. Egorshin, 1988, Gynecologic oncology.

Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration.

R. Alvarez, W. Kinney, M. Morris, 1996, Gynecologic oncology.

Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva.

L. Smith, L. Smith, D. Townsend, 1992, Gynecologic oncology.

Identification of a low-risk subset of patients with stage IB invasive squamous cancer of the cervix possibly suited to less radical surgical treatment.

D. Hodge, D. Ballard, K. Podratz, 1995, Gynecologic oncology.

Human papillomavirus testing in the prevention of cervical cancer.

S. Wacholder, M. Schiffman, N. Wentzensen, 2011, Journal of the National Cancer Institute.

State of the science: cervical cancer screening in transition.

H. Dinkelspiel, W. Kinney, 2014, Gynecologic oncology.

Cervical excisional treatment of young women: a population-based study.

J. Cuzick, C. Wheeler, W. Hunt, 2014, Gynecologic oncology.

Long-term survival and sequelae after surgical management of invasive cervical carcinoma diagnosed at the time of simple hysterectomy.

D. Ballard, K. Podratz, W. Kinney, 1992, Gynecologic oncology.

Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.

M. Sherman, R. Kurman, L. Hurley, 1999, Human pathology.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

M. Schiffman, P. Castle, T. Lorey, 2019, JAMA oncology.

Flow-cytometric DNA analysis of stages IB and IIA cervical carcinoma.

S. Cha, J. Katzmann, K. Podratz, 1992, Gynecologic oncology.

Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix.

G W Morley, S J Soong, S. Soong, 1989, Gynecologic oncology.

Stage at Diagnosis and Mortality in Patients with Adenocarcinoma and Adenosquamous Carcinoma of the Uterine Cervix Diagnosed as a Consequence of Cytologic Screening

R. Hiatt, H. Sung, G. Sawaya, 2003, Acta Cytologica.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

R. Hiatt, M. Sherman, K. M. McIntosh, 1999, JAMA.

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Diane Solomon, Nicolas Wentzensen, Mark Schiffman, 2013, Obstetrics and gynecology.

Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology.

J. Cuzick, C. Wheeler, M. Schiffman, 2019, Archives of pathology & laboratory medicine.

Age‐stratified 5‐year risks of cervical precancer among women with enrollment and newly detected HPV infection

M. Schiffman, P. Castle, T. Lorey, 2015, International journal of cancer.

Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Relationship of Atypical Glandular Cell Cytology, Age, and Human Papillomavirus Detection to Cervical and Endometrial Cancer Risks

P. Castle, T. Lorey, W. Kinney, 2010, Obstetrics and gynecology.

Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern California

M. Schiffman, P. Castle, T. Lorey, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting

M. Schiffman, P. Castle, T. Lorey, 2019, International journal of cancer.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

M. Schiffman, M. Einstein, D. Solomon, 2013, Journal of lower genital tract disease.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting

P. Castle, T. Lorey, W. Kinney, 2009, Obstetrics and gynecology.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

E. J. Mayeaux, M. Schiffman, M. Einstein, 2015, Gynecologic oncology.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

E. J. Mayeaux, M. Schiffman, M. Einstein, 2015, Gynecologic oncology.

Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance

E. J. Mayeaux, Robert A. Goulart, M. Schiffman, 2015, Obstetrics and gynecology.

The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer

P. Castle, T. Lorey, W. Kinney, 2010, Obstetrics and gynecology.

Whole abdomen radiotherapy for patients with peritoneal dissemination of endometrial adenocarcinoma.

Susan W Lee, A. Russell, W. Kinney, 2003, International journal of radiation oncology, biology, physics.

Surgical treatment of patients with stages IB and IIA carcinoma of the cervix and palpably positive pelvic lymph nodes.

D. Hodge, D. Ballard, K. Podratz, 1995, Gynecologic oncology.

Chemoradiation for primary invasive squamous carcinoma of the vagina

L. Smith, L. Smith, G. Leiserowitz, 2003, International Journal of Gynecologic Cancer.

Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Special commentary: patient safety and the next generation of HPV DNA tests.

M. Stoler, P. Castle, W. Kinney, 2010, American journal of clinical pathology.

Potential harms outweigh benefits of indefinite monitoring of stable adnexal masses.

W. Kinney, E. Suh-Burgmann, 2015, American journal of obstetrics and gynecology.

Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan

R. Hiatt, H. Sung, G. Sawaya, 2000, Journal of lower genital tract disease.

Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

The population impact of human papillomavirus/cytology cervical cotesting at 3‐year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

M. Schiffman, P. Castle, T. Lorey, 2016, Cancer.

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

M. Schiffman, N. Wentzensen, P. Castle, 2015, Journal of the National Cancer Institute.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

M. Schiffman, P. Castle, T. Lorey, 2014, Journal of the National Cancer Institute.

Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice.

S. Wacholder, M. Schiffman, P. Castle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cervical cancer control, priorities and new directions

J. T. Cox, P. Coursaget, F. X. Bosch, 2004, International journal of cancer.

Recommendations for a national agenda to substantially reduce cervical cancer

G. Zimet, M. Fouad, D. Saslow, 2013, Cancer Causes & Control.

A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results

E. J. Mayeaux, H. Lawson, P. Castle, 2016, Gynecologic oncology.

Accuracy and Efficiency of Deep-Learning–Based Automation of Dual Stain Cytology in Cervical Cancer Screening

N. Grabe, M. Schiffman, N. Wentzensen, 2020, Journal of the National Cancer Institute.

Cervical Cancer After Multiple Negative Cytologic Tests in Long-Term Members of a Prepaid Health Plan

R. Hiatt, H. Sung, G. Sawaya, 2005, Acta Cytologica.

J. Cuzick, C. Wheeler, M. Schiffman, 2016, Obstetrics and gynecology.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

Human Papillomavirus DNA Testing in Routine Clinical Practice for Prediction of Underlying Cervical Intraepithelial Neoplasia 2/3+ at Initial Evaluation and in Follow-up of Women with Atypical Glandular Cell Papanicolaou Tests

G. Pawlick, W. Kinney, B. Fetterman, 2006 .

Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Risk of Cervical Precancer and Cancer in Women Aged 30 Years and Older With an HPV-Negative Low-Grade Squamous Intraepithelial Lesion Screening Result

J. T. Cox, P. Castle, T. Lorey, 2011, Journal of lower genital tract disease.

The low risk of precancer after a screening result of human papillomavirus‐negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management

J. Cuzick, M. Schiffman, P. Castle, 2014, Cancer cytopathology.

Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States

J. Cuzick, C. Wheeler, M. Stoler, 2023, International journal of cancer.

Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.

J. Cuzick, C. Wheeler, N. Joste, 2021, Gynecologic oncology.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

M. Schiffman, P. Castle, T. Lorey, 2018, Preventive medicine.

Screening Interval and Risk of Invasive Squamous Cell Cervical Cancer

R. Hiatt, H. Sung, G. Sawaya, 2003, Obstetrics and gynecology.

Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

J. T. Cox, P. Castle, T. Lorey, 2011, Gynecologic oncology.

Age-appropriate use of human papillomavirus vaccines in the U.S.

P. Castle, M. Husain, A. Glass, 2009, Gynecologic oncology.

Identifying Women With Cervical Neoplasia Using Human Papillomavirus DNA Testing for Equivocal Papanicolaou Results

R. Hiatt, M. Sherman, K. M. McIntosh, 1999 .

Protection against cervical cancer versus decreasing harms from screening - What would U.S. patients and clinicians prefer, and do their preferences matter?

W. Huh, W. Kinney, 2017, Preventive medicine.

Equal Management of Equal Risks: What Should be Used as the Standard for Cervical Cancer Prevention?

G. Sawaya, W. Kinney, R. Perkins, 2018, Journal of lower genital tract disease.

Human papillomavirus testing 2007–2012: Co‐testing and triage utilization and impact on subsequent clinical management

J. Cuzick, C. Wheeler, D. Saslow, 2015, International journal of cancer.

Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

M. Schiffman, P. Castle, T. Lorey, 2019, Preventive medicine.

Interobserver reproducibility and accuracy of p16/Ki‐67 dual‐stain cytology in cervical cancer screening

M. Schiffman, N. Wentzensen, P. Castle, 2014, Cancer cytopathology.

Invasive Cervical Cancer After a Positive Pap Test Result and Negative Human Papillomavirus Test Result.

P. Castle, T. Lorey, N. Wentzensen, 2021, Obstetrics and gynecology.

Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Screening history preceding a diagnosis of cervical cancer in women age 65 and older.

J. T. Cox, P. Castle, T. Lorey, 2012, Gynecologic oncology.

Outcomes From Ultrasound Follow-up of Small Complex Adnexal Masses in Women Over 50

W. Kinney, Y. Hung, E. Suh-Burgmann, 2014 .

The Value of Ultrasound Monitoring of Adnexal Masses for Early Detection of Ovarian Cancer

W. Kinney, E. Suh-Burgmann, E. SUH-BURGMANN, 2016, Front. Oncol..

Missed Opportunities for Cervical Cancer Screening of HMO Members Developing Invasive Cervical Cancer

R. Hiatt, H. Sung, G. Sawaya, 1998 .

A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15‐year cervical cancer screening experience at Kaiser Permanente Northern California

M. Schiffman, P. Castle, T. Lorey, 2020, International journal of cancer.

A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results

H. Lawson, P. Castle, W. Huh, 2016, Journal of lower genital tract disease.

Positive peritoneal cytology in stage I carcinoma of the cervix.

W. Kinney, P. Vogt, J. D. Trelford, 1995, Acta Cytologica.

Cervical Cancer Rates After the Transition From Annual Pap to 3-Year HPV and Pap

P. Castle, T. Lorey, H. Dinkelspiel, 2014, Journal of lower genital tract disease.

Recommendations for a national agenda to substantially reduce cervical cancer

Maria E Fernandez, G. Zimet, M. Fouad, 2013, Cancer Causes & Control.

Erratum: The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer (Obstet Gynecol (2010) 116 (76-84))

P. Castle, T. Lorey, W. Kinney, 2010 .

Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

M. Schiffman, M. Einstein, D. Solomon, 2013 .

Comprehensive control of human papillomavirus infections and related diseases.

M. Plummer, M. Poljak, J. Ferlay, 2013, Vaccine.

Risk of Cervical Precancer and Cancer in Women With Cervical Intraepithelial Neoplasia Grade 1 on Endocervical Curettage

T. Lorey, W. Kinney, B. Fetterman, 2013, Journal of lower genital tract disease.

Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.

P. Castle, T. Lorey, N. Wentzensen, 2024, Gynecologic oncology.

The population impact of human papillomavirus/cytology cervical cotesting at 3‐year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

M. Schiffman, P. Castle, T. Lorey, 2016, Cancer.

Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance

E. J. Mayeaux, M. Schiffman, M. Einstein, 2015, Journal of lower genital tract disease.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

S. Wacholder, M. Schiffman, P. Castle, 2011, The Lancet. Oncology.

Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive

M. Schiffman, P. Castle, T. Lorey, 2013, Journal of lower genital tract disease.

Age‐stratified 5‐year risks of cervical precancer among women with enrollment and newly detected HPV infection

M. Schiffman, P. Castle, T. Lorey, 2015, International journal of cancer.

Cervical Dysplasia: Original Research Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations Implications for Clinical Guidelines

J. Cuzick, M. Schiffman, P. Castle, 2022 .